These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 27888609)

  • 21. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs.
    Chan EW; He Y; Chui CS; Wong AY; Lau WC; Wong IC
    Obes Rev; 2013 May; 14(5):383-92. PubMed ID: 23331711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
    Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
    JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity.
    Hurren KM; Dunham MW
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):891-896. PubMed ID: 28636828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An up-to-date evaluation of lorcaserin hydrochloride for the treatment of obesity.
    Tchang BG; Abel B; Zecca C; Saunders KH; Shukla AP
    Expert Opin Pharmacother; 2020 Jan; 21(1):21-28. PubMed ID: 31693425
    [No Abstract]   [Full Text] [Related]  

  • 25. The effect of antiobesity drugs on waist circumference: a mixed treatment comparison.
    Chilton M; Dunkley A; Carter P; Davies MJ; Khunti K; Gray LJ
    Diabetes Obes Metab; 2014 Mar; 16(3):237-47. PubMed ID: 23964810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study.
    Smith SR; Garvey WT; Greenway FL; Zhou S; Fain R; Pilson R; Fujioka K; Aronne LJ
    Obesity (Silver Spring); 2017 May; 25(5):857-865. PubMed ID: 28440045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis.
    Nguyen CT; Zhou S; Shanahan W; Fain R
    Clin Ther; 2016 Jun; 38(6):1498-1509. PubMed ID: 27206567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of lorcaserin on glycemic parameters in patients with type 2 diabetes mellitus.
    Magkos F; Nikonova E; Fain R; Zhou S; Ma T; Shanahan W
    Obesity (Silver Spring); 2017 May; 25(5):842-849. PubMed ID: 28345809
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicentre, placebo-controlled trial of lorcaserin for weight management in Chinese population.
    Lu CW; Chang CJ; Yang YC; Lin WY; Huang KC
    Obes Res Clin Pract; 2018 Jul; 12(5):465-471. PubMed ID: 30033356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of lorcaserin in different age groups: a post hoc analysis of patients from the BLOOM, BLOSSOM and BLOOM-DM studies.
    Fujioka K; Malhotra M; Perdomo C; Apovian CM
    Obes Sci Pract; 2019 Apr; 5(2):120-129. PubMed ID: 31019729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of lorcaserin for the treatment of obesity.
    Berlie HD; Hurren KM
    Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1053-9. PubMed ID: 23802690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial.
    Bohula EA; Scirica BM; Fanola C; Inzucchi SE; Keech A; McGuire DK; Smith SR; Abrahamsen T; Francis BH; Miao W; Perdomo CA; Satlin A; Wiviott SD; Sabatine MS
    Am Heart J; 2018 Aug; 202():39-48. PubMed ID: 29803985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Observational Comparative Effectiveness of Pharmaceutical Treatments for Obesity within the Veterans Health Administration.
    Grabarczyk TR
    Pharmacotherapy; 2018 Jan; 38(1):19-28. PubMed ID: 29044720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women.
    Smith SR; Prosser WA; Donahue DJ; Morgan ME; Anderson CM; Shanahan WR;
    Obesity (Silver Spring); 2009 Mar; 17(3):494-503. PubMed ID: 19057523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lorcaserin. In obesity: unacceptable risks.
    Prescrire Int; 2014 May; 23(149):117-20. PubMed ID: 24926508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release.
    Garvey WT; Ryan DH; Bohannon NJ; Kushner RF; Rueger M; Dvorak RV; Troupin B
    Diabetes Care; 2014 Dec; 37(12):3309-16. PubMed ID: 25249652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel oral anti-obesity agents: new perspectives with lorcaserin?
    Gallwitz B
    Drugs; 2013 Apr; 73(5):393-5. PubMed ID: 23532530
    [No Abstract]   [Full Text] [Related]  

  • 38. Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
    Fujioka K; Braverman-Panza J
    J Fam Pract; 2016 Jul; 65(7 Suppl):S16-23. PubMed ID: 27565106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of lorcaserin on cardiometabolic risk factors in overweight and obese patients: A systematic review and meta-analysis.
    Kuo HH; Wang KT; Lee YH; Lin PL; Liu ME; Lin CY; Liu LY
    J Clin Pharm Ther; 2020 Feb; 45(1):35-44. PubMed ID: 31544267
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.